Brief: Sanofi: EC Approves Sarclisa
08/06/2026 06:11
BRIEF-Sanofi: EC Approves Sarclisa June 8 (Reuters) - Sanofi SA SASY.PA:
EUROPEAN COMMISSION APPROVES SARCLISA SUBCUTANEOUS FOR MULTIPLE MYELOMA ACROSS ALL EXISTING IV INDICATIONS
SARCLISA FIRST ANTICANCER THERAPY IN EU ADMINISTERED VIA ON-BODY INJECTOR AND MANUAL SC INJECTION
70% OF PATIENTS REPORTED SATISFACTION WITH SARCLISA SC VIA OBI IN IRAKLIA PHASE 3 STUDY
SARCLISA SUBCUTANEOUS WITH ON-BODY INJECTOR SHOWS EFFICACY ACROSS ALL APPROVED IV INDICATIONS
Source text: nGNE1fFf52
Further company coverage: SASY.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))
Recent news on Sanofi SA
See all newsFDA approves expanded use of Sanofi's type 1 diabetes drug (updated)
Brief: FDA Approves Tzield For Pediatric Stage 3 Type I Diabetes
FDA approves Sanofi's drug for stage 3 type 1 diabetes in children
European shares steady as investors weigh US-Iran flare-up (updated)
European shares steady as investors cling to Mideast peace hopes